Pancreatic Cancer Research

ResearcherJiangsu UniversityNo recent work listed

Zhengfa Mao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5008358937, A5112255636. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2012: 3 papers · 2013: none · 2014: 4 papers · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper

Papers 12

  1. Corrigendum to "Krüppel-like factor 9 suppressed tumorigenicity of the pancreatic ductal adenocarcinoma by negatively regulating frizzled-5" [Biochem. Biophys.… Last author DOI 10.1016/j.bbrc.2019.01.086↗
  2. Krüppel-like factor 9 suppressed tumorigenicity of the pancreatic ductal adenocarcinoma by negatively regulating frizzled-5. Last author DOI 10.1016/j.bbrc.2018.03.229↗
  3. KLF9 Is a Prognostic Indicator in Human Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.11756↗
  4. Secreted protein acidic and rich in cysteine enhances the chemosensitivity of pancreatic cancer cells to gemcitabine. First author DOI 10.1007/s13277-015-4044-4↗
  5. FOXC2 is up-regulated in pancreatic ductal adenocarcinoma and promotes the growth and migration of cancer cells. Co-author DOI 10.1007/s13277-015-4607-4↗
  6. Cyclooxygenase 2 promoted the tumorigenecity of pancreatic cancer cells. First author DOI 10.1007/s13277-013-1301-2↗
  7. NOV promoted the growth and migration of pancreatic cancer cells. Co-author DOI 10.1007/s13277-013-1418-3↗
  8. Secreted protein acidic and rich in cysteine inhibits the growth of human pancreatic cancer cells with G1 arrest induction. Co-author DOI 10.1007/s13277-014-2315-0↗
  9. [Mechanism of SPARC-enhanced chemosensitivity of pancreatic cancer cells to gemcitabine]. Co-author PMID 25030587↗
  10. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Co-author DOI 10.1007/s10238-011-0159-0↗
  11. IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Co-author DOI 10.1007/s13277-011-0273-3↗
  12. CCN1 promotes tumorigenicity through Rac1/Akt/NF-κB signaling pathway in pancreatic cancer. Co-author DOI 10.1007/s13277-012-0434-z↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xu‐Qing Wang · 9 shared papers, 2012–2019 · strength 0.59
  2. Jianxin Zhang · 6 shared papers, 2014–2019 · strength 0.44
  3. Xin Fan · 6 shared papers, 2012–2018 · strength 0.36
  4. Peiyu Ji · 2 shared papers, 2018–2019 · strength 0.21
  5. Lei Cui · 4 shared papers, 2012–2016 · strength 0.19
  6. Sheng-Chun Dang · 3 shared papers, 2014–2016 · strength 0.17
  7. Jianxin Zhang · 3 shared papers, 2012–2016 · strength 0.14
  8. Lei Cui · 3 shared papers, 2012–2016 · strength 0.14
  9. Jixiang Chen · 2 shared papers, 2014–2016 · strength 0.11
  10. Yong Zhang · 1 shared paper, 2017 · strength 0.08
  11. Christoph W. Michalski · 1 shared paper, 2017 · strength 0.08
  12. Yefei Rong · 2 shared papers, 2012 · strength 0.06
  13. Dayong Jin · 2 shared papers, 2012 · strength 0.06
  14. Wenjun Li · 1 shared paper, 2014 · strength 0.06
  15. Ying Wang · 1 shared paper, 2014 · strength 0.05
  16. Wenhui Lou · 1 shared paper, 2012 · strength 0.03
  17. Dansong Wang · 1 shared paper, 2012 · strength 0.03
  18. Wenhui Lou · 1 shared paper, 2012 · strength 0.03
  19. Xinyu Qin · 1 shared paper, 2012 · strength 0.03
  20. Tiantao Kuang · 1 shared paper, 2012 · strength 0.03
  21. Wenchuan Wu · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.